Key Highlights
- ImmunityBio (IBRX) shares increased 3% Monday following submission of an FDA compliance response
- FDA identified a television commercial and podcast discussing Anktiva as potentially false or misleading in March 2026
- Company maintains the television commercial never aired publicly; podcast has been taken down from all platforms
- New compliance measures include mandatory leadership training and enhanced review procedures
- QUILT-2.005 trial interim results support adequate statistical power for planned Q4 2026 supplemental application
Shares of ImmunityBio (IBRX) advanced 3% during Monday’s trading session following the biotechnology firm’s official response to FDA concerns regarding marketing compliance for Anktiva, its bladder cancer treatment.
The regulatory agency’s Office of Prescription Drug Promotion identified a television commercial and podcast content in a letter dated March 13, 2026, characterizing both as containing false or misleading information.
In its formal reply, ImmunityBio contested at least one allegation — asserting that the television advertisement referenced by regulators was never publicly broadcast or distributed through any media channels.
The disputed podcast included statements from company Founder and Executive Chairman Dr. Patrick Soon-Shiong. ImmunityBio clarified that his remarks were intended to express prospective views regarding the company’s developmental programs rather than make representations about currently approved therapeutic uses.
The company has since eliminated the podcast from its official website and contacted third-party platforms to request its removal from their hosting services.
CEO Richard Adcock emphasized that the organization “takes promotional compliance with the utmost seriousness” and highlighted the importance of maintaining clear boundaries between investigational therapies and FDA-approved product indications.
Regarding remedial measures, the biotech firm is establishing mandatory compliance training for executives, strengthening Promotional Review Committee oversight mechanisms, and engaging outside regulatory advisors to evaluate future high-profile communications.
Securities Litigation Emerges
The FDA correspondence created complications beyond regulatory scrutiny. Several law firms have initiated securities class action litigation, claiming shareholders were deceived regarding Anktiva’s therapeutic profile and the company’s advertising compliance standards.
This represents a significant concern. Regardless of whether the FDA finds the company’s response acceptable, the pending litigation creates additional uncertainty for investors already monitoring a business with substantial cash consumption and reliance on a single commercial product.
Clinical Progress Provides Balance
Despite these challenges, clinical advancement for Anktiva continues. Interim analysis from the pivotal QUILT-2.005 clinical trial revealed that an independent monitoring committee verified the 366-participant randomized investigation — evaluating Anktiva combined with BCG versus BCG monotherapy — possesses sufficient statistical power to support the anticipated supplemental BLA submission in Q4 2026.
This regulatory submission would seek approval for BCG-naïve non-muscle invasive bladder cancer patients, representing a broader indication than Anktiva’s existing authorization.
Anktiva currently holds approval for use with Bacillus Calmette-Guérin in adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer featuring carcinoma in situ, with or without papillary tumors.
Financial analyst projections show considerable variation. Conservative estimates anticipate $1.2 billion in revenue generation and $435.5 million in earnings by 2029 — necessitating approximately 119% compound annual revenue growth from the present operating loss position of -$351.4 million.
Optimistic projections extend to $1.6 billion in revenue and $671.9 million in earnings within the same timeframe.
The Q4 2026 supplemental BLA submission represents the nearest significant milestone for the company.
